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Prevention of mitochondrial impairment by
inhibition of protein phosphatase 1 activity
in amyotrophic lateral sclerosis
So Yoen Choi1,2, Ju-Hyun Lee1, Ah-Young Chung3, Youhwa Jo1, Joo-ho Shin4, Hae-Chul Park 3, Hyun Kim1,
Rodrigo Lopez-Gonzalez2, Jae Ryun Ryu1 and Woong Sun 1
Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease caused by progressive loss of motor neurons
(MNs) and subsequent muscle weakness. These pathological features are associated with numerous cellular changes,
including alteration in mitochondrial morphology and function. However, the molecular mechanisms associating
mitochondrial structure with ALS pathology are poorly understood. In this study, we found that Dynamin-related
protein 1 (Drp1) was dephosphorylated in several ALS models, including those with SOD1 and TDP-43 mutations, and
the dephosphorylation was mediated by the pathological induction of protein phosphatase 1 (PP1) activity in these
models. Suppression of the PP1-Drp1 cascade effectively prevented ALS-related symptoms, including mitochondrial
fragmentation, mitochondrial complex I impairment, axonal degeneration, and cell death, in primary neuronal culture
models, iPSC-derived human MNs, and zebrafish models in vivo. These results suggest that modulation of PP1-Drp1
activity may be a therapeutic target for multiple pathological features of ALS.
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegen-
erative disorder characterized by progressive and selec-
tive loss of motor neurons (MNs)1,2. The clinical
symptoms of ALS include muscle weakness, dysphagia,
and speech problems, and the disorder eventually leads to
death from dyspnea within three to 5 years of diag-
nosis3,4. Most ALS cases are sporadic, and roughly 10% of
them are familial forms caused by various genetic
mutations in specific genes, including superoxide dis-
mutase 1 (SOD1), transactive response DNA-binding
protein-43 (TDP-43), and chromosome 9 open reading
frame 72 (C9orf72)5,6. Mutations in these genes are also
found in the sporadic form of ALS1. For example,
hexanucleotide repeat expansion of C9orf72 was identi-
fied in a large proportion of both familial and sporadic
forms of ALS patients, suggesting that somatic or de novo
mutations in causative genes may also be responsible for
sporadic ALS7,8. Although the causes of ALS may differ,
most ALS cases exhibit common pathological features
with biochemical/cellular hallmarks such as protein
aggregations, abnormal Ca2+ buffering9, glutamate exci-
totoxicity10, glial activation11, disruption of RNA meta-
bolism12, and mitochondrial dysfunction13,14. Therefore,
it has been postulated that multiple cellular changes are
involved in the progression of ALS symptoms, making it
difficult to develop effective treatments. Although rilu-
zole and edaravone are the drugs for ALS currently
approved by FDA, their efficacies are modest in clinical
trials, and their pharmacological targets appear to be
different15–17. It is, therefore, of great importance to
develop novel treatments targeting several of the com-
mon pathological features responsible for the complex
nature of ALS pathology.
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Mitochondrial dysfunction is commonly found in both
familial and sporadic ALS cases18–20, suggesting that mito-
chondria may serve as an important hub for ALS patho-
physiology. For example, it has been reported that
mitochondria were morphologically fragmented and func-
tionally deteriorated from the pre-symptomatic period in
patients and mouse models of ALS (SOD1 G93A)21,22.
C9ORF72-associated poly(GR) compromises mitochondrial
function and induces mitochondrial fragmentation, leading
to DNA damage and an increase in cell death23,24. In
sporadic ALS cases, mitochondrial morphological abnorm-
alities have been detected in the anterior horn of the spinal
cord19. Mitochondria are essential for cellular ATP pro-
duction, and MNs require large amounts of energy from the
mitochondria in order to function. Thus, it has been sug-
gested that MNs are one of the most vulnerable types of cells
to mitochondrial dysfunction25–27. On the other hand, the
morphological changes in the mitochondria in ALS pathol-
ogy may hint at additional links between mitochondria and
MN function. The morphological dynamics of mitochondria
are homeostatically controlled by the balance between con-
tinuous fission and fusion, and this is necessary for the
maintenance of mitochondrial quality28,29. Mitochondrial
dynamics are controlled by large GTPase dynamin-related
proteins, including Dynamin-related protein 1 (Drp1),
Mitofusin1/2 (MFN1/2), and Optic atrophy 1 (Opa1)30.
Recently, it was reported that the expression of Drp1 was
induced in the spinal cord of SOD1 G93Amodel mice31, and
the suppression of Drp1 inhibited mutant SOD1-induced
mitochondrial fragmentation and cell death in vitro2, sug-
gesting that alteration of Drp1 activity may mediate at least
some aspects of MN degeneration in ALS. However, the
precise molecular mechanisms underlying the Drp1 function
and ALS pathology are yet to be described.
In an attempt to identify novel therapeutic targets for
ALS, we examined whether Drp1-dependent mitochon-
drial dynamics are an effective target for ALS therapy and
explored the upstream mechanism modulating Drp1
activity in ALS models. To this end, we identified that
Drp1 is pathologically dephosphorylated in SOD1 G93A
mice, and the blockade of Drp1 activity prevents cell
death induced by the expression of mutant SOD1 or TDP-
43. Furthermore, we identified PP1 as a phosphatase
responsible for the dephosphorylation of Drp1 and found
that the inhibition of PP1 activity suppresses neurotoxi-
city in several ALS models. Based on our observations, we
propose that pathological induction of PP1 plays a key
role in the progression of cellular events associated with
ALS, providing novel therapeutic targets for ALS.
Materials and methods
Animal model and treatment
SOD1 G93A transgenic mice were maintained as a
hemizygous line by mating with wild type C57BL/6J mice.
To distinguish between SOD1 G93A and WT mice, pups
were genotyped with DNA obtained from their toes, using
the PCR method. To create the ALS zebrafish models,
embryos from Tg(olig2-egfp) zebrafish, whose MN axons
exhibit EGFP32,33, were microinjected with 1.76 ng RNA
(SOD1 G93A and TDP-43 Q331K), synthesized by T7
RNA polymerase. Embryos were treated with Mdivi-1
(2.5 nM, Sigma, Cat. 338967-87-6), I-2 (200 nM, Milli-
pore, Cat. 14-162), or Okadaic acid (100 nM, Sigma, Cat.
O8010) 24 h after microinjection, and then once again the
following day. The animal models were randomly
assigned to experimental groups.
Primary cortical neuron culture
The Cerebral cortices were dissected from WT rat or
mouse embryos (E16~17) and chopped using a micro scissor.
The tissues were incubated in 0.05% Trypsin-EDTA at 37 °C
for 10min and then centrifuged at 1000 rpm for 1min. The
dissociated cells were washed with HBSS and re-suspended
in complete medium, containing NeurobasalTM medium
(Invitrogen, Cat. 21103) supplemented with B27 (GIBCO
BRL, Cat. 17504044), L-glutamic acid (GIBCO BRL), L-
glutamine (GIBCO BRL), and penicillin–streptomycin
(GIBCO BRL). The cells were plated onto poly-D lysine pre-
coated coverslips (2 × 105 cells/well) and cultured in com-
plete medium. After 3 days, the complete medium was
replaced with incomplete medium, containing NeurobasalTM
medium supplemented with B27, L-glutamine, and
penicillin–streptomycin. On 4 days in vitro, 50 μM Mdivi-1
or I-2 (NEB, Cat. P0755L) were treated for 24 or 72 h. In
some cases, shDrp1 (5'-GAA GAG TGT AAC TGA TTC A-
3’) or shFis1 (5'-CAG CGG GAT TAT GTC TTC T-3’)
sequences were inserted into the BglII/HindIII site of the p-
Super GFP vector. shPP1α (5'-GCA GCT GAC AGA GAA
CGA GAT-3’), shPP1β (5'-GCT AAA CGA CAG TTG GTA
ACC-3’) or shPP1γ (5'-GGG TAT GAT CAC AAA GCA
AGC-3’) sequences were inserted into the PacI site of the
FUGW-GFP vector, and the resultant vectors were cotrans-
fected with ALS-related mutants (SOD1 G93A, TDP-43
Q331K). Three days after transfection, the pyknotic and
activated caspase-3 labeled cells were counted.
MN differentiation and pharmacological treatments
Differentiation of iPSCs into MNs was performed as
described by Lopez-Gonzalez et al.21. Briefly, iPSCs were
plated and expanded in an mTSER1 medium (Stem Cell
Technologies Cat. 5875) in Matrigel-coated wells (Corn-
ing Cat. 354230). Twenty-four hours after plating, the
culture medium was replaced with neuroepithelial pro-
genitor (NEP) medium, containing DMEM/F12 (Invitro-
gen Cat. 12660-012):neurobasal medium (Invitrogen Cat.
21103049) at 1:1, 0.5 × N2 (Thermo-Fisher Cat. 17502-
048), 0.5 × B27 (Thermo-Fisher Cat. 17504-044), 0.1 mM
ascorbic acid (Sigma Cat. A4403), 1 × Glutamax
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(Invitrogen35050061), 3 μM CHIR99021 (Stem Cell
Technologies Cat. 72054), 2 μM DMH1 (Stem Cell
Technologies Cat. 73634), and 2 μM SB431542 (Stemgent
Cat. 040010-10). After 6 days, NEPs were dissociated with
accutase, split 1:6 into Matrigel-coated wells, and cultured
for 6 days in motor neuron progenitor induction medium
(NEP) with 0.1 μM retinoic acid (Sigma Cat. R2625) and
0.5 μM purmorphamine (Calbiochem Cat. 540220).
Motor neuron progenitors were dissociated with accutase
to generate neurosphere suspension cultures. After a
further 6 days, the cultures were dissociated into single
cells, plated on laminin-coated plates/coverslips (TTE
laboratories Cat. WN354087) in a motor neuron differ-
entiation medium containing 0.5 μM retinoic acid, 0.1 μM
purmorphamine, and 0.1 μM Compound E (Stem Cell
Technologies Cat. 73954) for 2 weeks and then in the
same medium without Compound E for up to 3 weeks.
iPSC-derived motor neurons from controls lines 35L11,
37L20, and 24L2, and TDP-43 mutant lines 292 (M337V),
290 (Q343R), and 36L10 (A90V) were treated from
1 week after plating with I-2 for an additional 2 weeks,
with the medium changed twice a week. After that, the
cells were fixed for imaging analysis.
Western blot
The lumbar region of the spinal cord was collected from
WT and SOD1 G93A mice and sonicated in a lysis buffer
(50 mM Tris-Cl pH 7.4, 150mM NaCl, 10% Glycerol, 1%
Triton-X100 and 1mM EDTA). After protein quantifi-
cation using the BCA method, 30 µg of protein was loaded
per well and separated by SDS-PAGE. The loaded protein
was transferred to a PVDF membrane, and this membrane
was incubated in a blocking solution (3% BSA/1 ×TBST)
for 1 h. The membrane was incubated with primary
antibody diluted 1:1000 with blocking solution overnight
at 4 °C, then washed three times in 1xTBST and incubated
with secondary antibody diluted 1:5000 with 5% Skim
Milk/1xTBST. The antibodies used were anti-Drp1 (BD,
Cat. 611113), anti-phospho Drp1 S616 (Cell signaling,
Cat. 3455), anti-Fis1 (Abcam, Cat. Ab96764), anti-PP1α
(Santa Cruz, Cat. sc-443), anti-phospho-PP1α (Cell Sig-
naling, Cat. #2581), PP1β (Santa Cruz, Cat. sc-373782),
PP1γ (Santa Cruz, Cat. sc-6109), and anti β-actin (Sigma,
Cat. A5441). The secondary antibodies used were anti-
mouse and anti-rabbit IgG conjugated to horseradish
peroxidase. The membrane was washed three times in
1xTBST, and the signals expressed by the protein were
visualized using an ECL kit (Thermo, Cat. 32106).
Immunohistochemistry
SOD1 G93A mice of each pathological stage were per-
fused in 4% paraformaldehyde, and the lumbar regions of
the spinal cord were dissected. The tissues were post-fixed
overnight at 4 °C. The fixed tissues were soaked in 30%
sucrose/1× PBS for cryo-protection. The lumbar regions
of the spinal cord were cut serially into sections 40 μm
thick on a cryostat, and these were transferred into 50%
glycerol in PBS. The sections were blocked in 1xPBS
containing 3% BSA and 0.2% Triton-X100 for 30min at
room temperature. After blocking, tissues were incubated
with primary antibody overnight at 4 °C and washed three
times in 1× PBS. The primary antibodies used were
phospho-DRP1 S616 (Cell Signaling, Cat. 3455), DRP1
(BD, Cat. 611113), and ChAT (Millipore, Cat. AB144P).
The tissues were incubated with fluorescence-labeled
secondary antibody and Hoechst33342 (10 μg/ml; Sigma,
St. Louis, MO) for 30 min at room temperature and
washed three times in 1× PBS. They were then mounted
on slides and observed using a fluorescence or confocal
microscope (Zeiss, Goettingen, Germany).
PP1 activity assay
PP1 activity was measured by the ProFluor Ser/Thr
PPase assay kit (Promega, Cat. V1260). This assay is based
on the dephosphorylation of a phosphorylated bisamide
rhodamine 110 peptide substrate. In order to carry out a
PP1 activity assay of the lumbar spinal cord, the tissue was
sonicated in a lysis buffer (5M NaCl, 1 M Tris-Cl, pH 7.5,
0.5M EDTA, 0.5M EGTA, 0.2M Na3VO4, 0.1M PMSF)
and centrifuged at 10,000 rpm for 10 min. Following
centrifugation, the supernatant was divided into two tubes
and treated with either 0.2 nM (for PP2A inhibition) or
1 μM okadaic acid (for PP1 inhibition). The level of PP1
activity of each sample was measured based on the
absorbance at 488 nm of nonphosphorylated S/T PPase
R110 substrate and then normalized by protein levels
(BCA assay). Relative PP1 activity was calculated as the
value of phosphatase activity level (treated with 0.2 nM
okadaic acid) minus the value of background phosphatase
activity (treated with 1 μM okadaic acid)34.
Assay of NADH dehydrogenase and complex I activity of
mitochondria
In order to carry out a histological assay of NADH
dehydrogenase, the lumbar spinal cord was snap-frozen
in pre-chilled isopentane and sectioned using a cryostat.
Phosphate buffer (0.343 g NaH2PO4 in 100 ml H2O) and
NBT (250 mg nitro blue tetrazolium in 100 ml H2O)
were prepared. The sections were incubated in a solu-
tion containing 5 mg NADH, 1 ml saline, 1 ml phos-
phate buffer, and 4 ml NBT with 2 ml distilled water.
After incubation for 30 min at room temperature in
humidity chamer, the sections were rinsed in distilled
water and observed using a microscope. The mito-
chondrial complex I activity of the lumbar spinal cord
and cultured neurons was measured using a microplate
assay kit (Abcam, Cat. Ab109721) according to the
manufacturer’s instruction35.
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Measurement of mitochondrial membrane potential (ΔΨm)
and velocity
Cultured cortical neurons were incubated with 500 nM
TMRM (tetramethylrhodamine, methyl ester; Invitrogen,
Cat. T668) for 30 min at 37 °C. The signal of TMRM was
imaged using a Carl Zeiss Observer Z1 with x630 mag-
nification, and its intensity was measured using ImageJ.
Statistical analysis
All samples or animals were assigned randomly, and the
experiment was performed in a blinded fashion. The data
were tested for differences between multiple groups using
one-way ANOVA followed by Scheffe’s or Tukey’s mul-
tiple comparisons tests for post hoc comparisons. Dif-
ferences between the means of two groups were tested
using the two-sided Student’s t-test.
Ethical statements
All animal maintenance and experimental procedures
were approved by members of the Laboratory Animal
Research Center at Korea University College of Medicine.
The use of hiPSCs was approved by the Institutional
Review Board and Ethics Committee at the University of
California, San Francisco (UCSF).
Results
Changes in mitochondrial fission proteins in ALS models
We first explored whether molecules responsible for the
morphological dynamics of mitochondria are altered in
SOD1 G93A (G93A) ALS model mice. Although the
expression level of Drp1 protein remained unaltered, the
phosphorylation level of Drp1 S616 was significantly
reduced at the onset period (when the mice were 100 days
old) (Fig. 1a). The expression level of Fis1, a receptor for
Drp1, also markedly increased during this period (Fig. 1a).
Immunohistochemical labeling of the lumbar spinal cord
with a phosphorylation-specific antibody against Drp1
S616 demonstrated that the reduction of Drp1 S616
phosphorylation mainly occurred in the MNs of G93A
mice (Fig. 1b). Next, we overexpressed G93A or TDP-43
Q331K (Q331K) associated with ALS in primary neurons
and found that these pathogenic mutants caused depho-
sphorylation of Drp1 (Fig. 1c). Collectively, these results
suggest that pathogenic stimuli associated with ALS cause
dephosphorylation of Drp1.
Prevention of Drp1 signaling reduces ALS-related
neurodegeneration
It has been reported that phosphorylation of Drp1 S616
is controlled by cdk5, which prevents the oligomerization
and subsequent mitochondrial localization of Drp1 in
neurons36. Dephosphorylation of Drp1 S616 and the
induction of Fis1 expression appear to promote Drp1-
dependent mitochondrial fission, which is associated with
neurodegeneration. In keeping with this, we found that
the overexpression of mutant G93A in primary cortical
neurons promoted mitochondrial fragmentation. How-
ever, suppression of Drp1 activation by transfection with
shDrp1 or shFis1, and treatment with a chemical inhibitor
(Mdivi-1), consistently prevented the mitochondrial frag-
mentation induced by ALS-related mutations, suggesting
that Drp1-Fis1 signaling is necessary for ALS-related
mitochondrial fragmentation (Fig. 2a and Supplementary
Fig. 1a). Next, we tested whether a blockade of Drp1-Fis1
would prevent neurodegeneration. Following transfection
with ALS-related mutant genes (SOD1 G93A and TDP-43
Q331K), neuronal death was enhanced, as assessed by
activated caspase-3 immunoreactivity (Fig. 2b–d) and
pyknotic nuclei (Supplementary Fig. 1b–d). Blocking Drp1
activation effectively prevented this cell death. Finally, we
tested the effects of a blockade of Drp1 activity in vivo
using an ALS zebrafish system (Fig. 2e). Degeneration of
motor axons induced by transient overexpression of SOD1
G93A or TDP-43 Q331K was readily detectable in the
models, but the blockade of Drp1 activity through treat-
ment with Mdivi-1 effectively prevented this axonal
degeneration. These results indicate that Drp1 activation
contributes to ALS-related neurodegeneration in vivo.
PP1 is involved in Drp1 dephosphorylation in G93A mice
Because dephosphorylation of Drp1 was found to be one
of the events associated with enhanced mitochondrial fis-
sion and neurodegeneration in the ALS models, we
explored the upstream phosphatase(s) responsible for this
dephosphorylation, under the assumption that upstream
phosphatase activation may cause the Drp1-dependent
mitochondrial defects found in ALS models (Fig. 3). The
blockade of PP1 by either of two selective inhibitors, can-
tharidin or inhibitor-2 (I-2), promoted the phosphorylation
of Drp1 S616 in a dose-dependent manner (Fig. 3a). Fur-
thermore, the dephosphorylation of Drp1 was completely
blocked by I-2 treatment in cortical neurons through G93A
overexpression (Fig. 3b). These observations suggest that
the activation of PP1 is responsible for the Drp1 depho-
sphorylation associated with ALS pathology. Moreover, we
found that the lumbar spinal cord of G93A mice exhibited
significantly higher PP1 activity in the symptomatic period
than in the pre-symptomatic period, and the enhanced PP1
activity was maintained until the end stage (Fig. 3c). It has
been reported that PP1 activity is regulated by its phos-
phorylation status, and dephosphorylation is required for
its activation37,38. Western blot analysis showed that PP1α
was activated in the pre-symptomatic period of ALS (Fig.
3d) and the phosphorylation of PP1 was decreased in the
ChAT+ neurons of G93A mouse at pre- and post-
symptomatic period, as well as in mSOD1 or TDP43
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expressing cortical neurons (Supplementary Fig. 2). Col-
lectively, these results demonstrated that pathologic
induction of PP1 activity may cause Drp1 activation and
subsequent induction of cell death in ALS models.
PP1 inhibition rescues neurons from neurodegeneration
To test whether PP1 inhibition is sufficient for the
prevention of Drp1-dependent mitochondrial fission in
the ALS model, we first examined whether PP1 inhibition
Fig. 1 Reduction of Drp1 S616 phosphorylation in the SOD1 G93A model. a p-Drp1 S616 and Fis1 protein expression levels in the lumbar spinal
cord of SOD1 G93A mice, and quantification of the relative expression of p-Drp1 S616 and Fis1, compared to WT. WT:p-DRPS616= 1.00 ± 0.12 (n= 3
mice), G93A: p-DRPS616= 0.64 ± 0.07 (n= 5 mice), WT:DRP1= 1.00 ± 0.12 (n= 3 mice), G93A: DRP1= 0.96 ± 0.06 (n= 5 mice), WT:Fis1= 0.24 ± 0.07
(n= 3 mice), G93A: Fis1= 0.70 ± 0.12 (n= 5 mice). Values are mean ± S.E.M. F(1,6)= 2.80, *P= 0.0311 for p-DRPS616; F(1,6)= 0.2721, P= 0.7946 for
DRP1; F(1,6)= 2.691, *P= 0.0.0360 for Fis1 graph by two-sided Student’s t-test. n.s.: not significant. b p-Drp1 S616 immunostaining in the spinal MN of
G93A and WT mice. The graph shows the ratio of intensity between p-Drp1 (green) and Drp1 (red) in ChAT-positive (blue; MN marker) neurons. WT
= 1.56 ± 0.04 (n= 316 ChAT+ neurons), G93A= 0.81 ± 0.01 (n= 346 ChAT+ neurons. Values are mean ± S.E.M. F(1,660)= 18.4, ****P < 0.0001 by
two-sided Student’s t-test. Scale bar, 100 μm. c Expression of p-Drp1 S616 in GFP-positive cortical neurons, following G93A or Q331K overexpression.
The graph shows the quantification of p-Drp1 S616 intensity. Arrowhead indicates a GFP-positive neuron. GFP= 100.00 ± 8.40 (n= 24 GFP+
neurons), G93A= 45.30 ± 3.73 (n= 25 GFP+ neurons), Q331K= 42.95 ± 4.2 (n= 20 GFP+ neurons). Values are mean ± S.E.M. F(2,66)= 29.75, ****P <
0.0001 by one-way ANOVA with Tukey’s post hoc analysis for multiple comparisons. Scale bar, 20 μm.
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Fig. 2 Effects of the blockade of Drp1 activity on ALS mutant-induced pathological features. Analysis of mitochondrial length ((a) N= 10 per
group) and active caspase-3-positive neurons (b–d) after 3 days following shRNA co-transfection or 25 μM Mdivi-1 treatment with G93A or Q331K
clone. Mitochondrial images have been embossed. GFP= 100.1 ± 6.54 (n= 31 GFP+ neurons), SOD G93A:CON= 74.55 ± 6.54 (n= 24 GFP+
neurons), SOD G93A:shDRP1= 197.3 ± 14.96 (n= 7 GFP+ neurons), SOD G93A:Mdivi= 105.5 ± 8.79 (n= 10 GFP+ neurons), SOD G93A:shFis1=
143.7 ± 17.38 (n= 9 GFP+ neurons). Values are mean ± S.E.M. F(1,53)= 3.239, **P= 0.0021 for GFP versus SOD G93A:CON by two-sided Student’s
t-test. F(3,46)= 33.54, *P= 0.0440, ****P < 0.0001 by one-way ANOVA with Tukey’s post hoc analysis for multiple comparisons in (a). GFP:CON=
100 ± 0.00 (n= 3 independent primary cultures), GFP:shDRP1= 95.25 ± 36.86 (n= 3 independent primary cultures), G93A:CON= 218 ± 25.18 (n= 3
independent primary cultures), G93A:shDRP1= 116.4 ± 7.52 (n= 3 independent primary cultures), Q331K:CON= 370 ± 38.99 (n= 3 independent
primary cultures), Q331K:shDRP1= 247.6 ± 18.38 (n= 3 independent primary cultures). Values are mean ± S.E.M. F(2,6)= 25.58, *P= 0.0473, ***P=
0.009 by one-way ANOVA with Tukey’s post hoc analysis for multiple comparisons. F(1,4)= 0.1289, P= 0.9037 for GFP:CON versus GFP:shDRP1; F(1,4)
= 3.869, #P= 0.0180 for G93A:CON versus G93A:shDRP1; F(1,4)= 2.846, #P= 0.0466 for Q331K:CON versus Q331K:shDRP1 by two-sided Student’s
t-test in (b). GFP:CON= 99.98 ± 0.03 (n= three independent primary cultures), GFP:Mdivi-1= 86.85 ± 24.57 (n= 3 independent primary cultures),
G93A:CON= 257 ± 15.85 (n= 3 independent primary cultures), G93A: Mdivi-1= 119.9 ± 17.42 (n= 3 independent primary cultures), Q331K:CON=
372 ± 60.06 (n= 3 independent primary cultures), Q331K: Mdivi-1= 171.9 ± 32.03 (n= 3 independent primary cultures). Values are mean ± S.E.M. F
(2,6)=14.53, *P= 0.0483, **P= 0.0041 by one-way ANOVA with Tukey’s post hoc analysis for multiple comparisons. F(1,4)= 0.5345, P= 0.6213 for
GFP:CON versus GFP:shDRP1; F(1,4)= 5.819, ##P= 0.0043 for G93A:CON versus G93A:shDRP1; F(1,4)= 2.922, #P=0 .0422 for Q331K:CON versus Q331K:
shDRP1 by two-sided Student’s t-test in (c). GFP:CON= 100 ± 0.03 (n= 3 independent primary cultures), GFP:shFis1= 94.73 ± 27.67 (n= 3
independent primary cultures), G93A:CON= 244 ± 4.88 (n= 3 independent primary cultures), G93A:shFis1= 125.8 ± 36.28 (n= 3 independent
primary cultures), Q331K:CON= 324.9 ± 18.34 (n= 3 independent primary cultures), Q331K: shFis1= 146 ± 38.89 (n= 3 independent primary
cultures). Values are mean ± S.E.M. F(2,6)= 108.1, ***P= 0.0002, ****P < 0.0001 by one-way ANOVA with Tukey’s post hoc analysis for multiple
comparisons. F(1,4)= 0.1922, P= 0.8569 for GFP:CON versus GFP:shDRP1; F(1,4)= 3.24, #P= 0.0317 for G93A:CON versus G93A:shDRP1; F(1,4)= 2.922,
#P= 0.0141 for Q331K:CON versus Q331K:shDRP1 by two-sided Student’s t-test in (d). Scale bar, 5 μm. e Zebrafish expressing G93A and Q331 with
2.5 μM Mdivi-1 daily treatment over 2 days, and the number of axonal defects of MNs counted for each of the four segments. Normal= 0.14 ± 0.1
(n= 14 zebrafish), G93A:CON= 2.93 ± 0.29 (n= 14 zebrafish), G93A:Mdivi-1= 0.2 ± 0.2 (n= 5 zebrafish), Q331K:CON= 3.43 ± 0.33 (n= 14 zebrafish),
Q331K:Mdivi-1= 0.45 ± 0.28 (n= 11 zebrafish). Values are mean ± S.E.M. F(2,39)= 47.44, ****P < 0.0001 by one-way ANOVA with Tukey’s post hoc
analysis for multiple comparisons.; F(1,17)= 5.445, ####P < 0.0001 for G93A:CON versus G93A:Mdivi-1, F(1,23)= 6.671, ####P < 0.0001 for Q331K:CON
versus Q331K: Mdivi-1 by two-sided Student’s t-test.
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prevented ALS-related mutant-dependent mitochondrial
fragmentation. PP1 has three catalytic isoforms, α, β and
γ, and I-2 can inhibit the action of all of them. Therefore,
in order to explore their importance, the effects of specific
shRNA against each isoform on mitochondrial fission
were tested. Interestingly, the suppression of PP1α, γ, and
I-2, but not PP1β, prevented the excessive fission of
mitochondria in G93A and Q331K-overexpressed pri-
mary cortical neurons (Fig. 4a, b and Supplementary Fig.
3). Next, we tested whether suppression of PP1 prevented
SOD1 G93A and TDP-43 Q331K-induced cell death.
PP1 suppression by I-2 and shPP1γ reduced the number
of active caspase-3-positive or pyknotic cells in the ALS-
related mutant gene-overexpressed neurons (Fig. 4c, d).
On the other hand, we found that the suppression of PP1α
by shRNA significantly enhanced cell death. Yet the
suppression of PP1 β and γ by shRNA significantly
reduced the number of pyknotic cells in SOD1 G93A- or
TDP-43 Q331K-overexpressed neurons (Fig. 4d). These
results indicate that different PP1 isoforms may mediate
different outcomes in ALS pathology via different substrate
specificities. Furthermore, we also found that I-2 prevented
the ALS-related mutant-induced retardation of axonal
growth in zebrafish models (Fig. 4e, f). Expression of SOD1
G93A and/or TDP-43 Q331K reduced axonal growth,
whereas I-2, shPP1α, and shPP1γ each restored axonal
growth to a level equal to the control. Interestingly, this
growth-restoring effect was not observed in Mdivi-1
treatments, suggesting that retardation of axonal growth
was not entirely dependent on Drp1 activation and that
PP1 may have additional targets for the progression of
ALS-related axonal degeneration/growth retardation.
Blockade of PP1 restores mitochondrial respiratory
functions
Because the mitochondrial bioenergetics is expected to
influence axonal growth, we tested whether PP1 activity is
also associated with the alteration of mitochondrial
respiratory complex activities (Fig. 5). It has been reported
that complex I activity is primarily affected in G93A
mice39, and we confirmed that NADH dehydrogenase,
which represents mitochondrial complex I activity, was
substantially reduced in the lumbar spinal cord of G93A
mice, compared to WT (Fig. 5a). Next, we tested whether
Fig. 3 Dephosphorylation of the site S616 of Drp1 by PP1 and the increase in PP1 activity in the lumbar spinal cord of G93A mice.
a Western blot analysis of p-Drp1 S616 and Drp1 expression level in primary cortical neuron with Cantharidin (for 1 h) or I-2 (for 1 day) treatment.
b Representative immunostaining image of p-Drp1 S616 (red) in GFP+ primary cortical neuron with or without 80 nM I-2 treatment for 24 h.
Arrowhead indicates the GFP-positive neuron. Scale bar, 20 μm. c PP1 activity in the lumbar spinal cord of G93A and WT mice at 60, 100, and 200 days
of age. WT:Pre= 100 ± 7.79 (n= 3 mice), G93A:Pre= 125.9 ± 5.51 (n= 4 mice), WT:Onset= 100 ± 17.35 (n= 3 mice), G93A: Onset= 166 ± 14.32 (n=
5 mice), WT:Post= 100 ± 18.35 (n= 5 mice), G93A:Post= 148.7 ± 9.58 (n= 5 mice). Values are mean ± S.E.M. F(1,5)= 2.811, *P= 0.0375 for WT:Pre
versus G93A:Pre; F(1,6)= 2.88, *P= 0.0281 for WT:Onset versus G93A:Onset; F(1,8)= .354, *P= 0.0464 for WT:Post versus G93A:Post by two-sided
Student’s t-test. d Western blot analysis of p-PP1 and PP1 expression in the lumbar spinal cord of G93A and WT mice at the onset period. The graph
shows the quantification of p-PP1 vs. PP1 intensity. WT= 1.00 ± 0.04 (n= 3 mice), G93A= 0.76 ± 0.05 (n= 3 mice). Values are mean ± S.E.M. F(1,4)=
3.832, *P= 0.0186 by two-sided Student’s t-test.
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a blockade of PP1 or Drp1 activity rescued the impair-
ment of mitochondrial function induced by the over-
expression of SOD1 G93A or TDP-43 Q331K, which
rapidly reduced complex I activity and mitochondrial
membrane potential (MMP; Fig. 5b, c)40–42. However, I-2
effectively prevented the reduction of mitochondrial
complex I activity and MMP in the mutant-overexpressed
neurons, while Mdivi-1 treatment failed to rescue these
functional impairments of the mitochondria. These results
suggest that pathological PP1 activity impaired mito-
chondrial respiration via a Drp1-independent route as well
as through Drp1-mediated mitochondrial impairments.
Blockade of PP1 activity alleviates ALS pathology in vivo
and in a human iPSC model
Next, we tested whether PP1 inhibition can effectively
prevent ALS-related neurodegeneration in a zebrafish
model. PP1 inhibition by treatment with I-2 or okadaic
acid (OA) prevented the axonal defects induced by SOD1
G93A or TDP-43 Q331K mutations (Fig. 6a, b). Inter-
estingly, I-2 restored the motor axonal length of mutant-
expressing MNs to a level equivalent to the control, which
was significantly superior to the effects of axonal elonga-
tion by the Mdivi-1 treatment (Fig. 6c). Finally, we also
tested whether these preventive effects of I-2 could be
Fig. 4 (See legend on next page.)
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observed in a human iPSC-derived MN model in vitro.
First, we differentiated multiple iPS cell lines from controls
and TDP43 mutants (mTDP-43;A90V, Q343R, M337V)43
into spinal MNs as described21. PP1 suppression induced
by I-2 treatment over 2 weeks inhibited mitochondrial
fragmentation, although in the periods between adminis-
trations of I-2, the mTDP group exhibited noticeable
mitochondrial shortening (Fig. 6a). As anticipated, the
number of active caspase-3-positive neurons and pyknotic
cells was lower in the I-2-treated mTDP group, suggesting
that inhibition of PP1 by I-2 suppresses neuronal toxicity
in several ALS-associated models. The prevention of
pathological PP1 activity could, therefore, be a viable
therapeutic target.
Discussion
Recent large-scale genetic analyses have revealed that
genes mediating many different biological cascades are
associated with ALS, suggesting that many different
pathways should merge into a common ‘hub’ cascade to
(see figure on previous page)
Fig. 4 Effects of the blockade of PP1 on G93A and Q331-induced neurodegeneration. a The representative image of mitochondria in the
neurite of GFP+ primary cortical neuron with 40 nM I-2 treatment or shRNA lenti-viral infection after transfection of dsRed-mito and mALS genes,
over 72 h. The mitochondrial image has been embossed using Photoshop and measured on the GFP+ cortical neuron. Scale bar, 5 μm. b Analysis of
mitochondrial length in (a). GFP:CON= 1.00 ± 0.06 (n= 29 GFP+ neurons), GFP:shPP1α= 1.1 ± 0.09 (n= 17 GFP+ neurons) GFP:shPP1β=0.79 ± 0.87
(n= 7 GFP+ neurons), GFP:shPP1γ= 1.08 ± 0.05 (n= 27 GFP+ neurons), GFP:I-2= 0.96 ± 0.05 (n= 30 GFP+ neurons), G93A:CON= 0.7 ± 0.02 (n= 30
GFP+ neurons), G93A:shPP1α= 1.00 ± 0.4 (n= 33 GFP+ neurons), G93A:shPP1β= 0.66 ± 0.02 (n= 30 GFP+ neurons), G93A:shPP1γ= 0.99 ± 0.05
(n= 20 GFP+ neurons), G93A:I-2= 1.04 ± 0.06 (n= 30 GFP+ neurons), Q331K:CON= 0.65 ± 0.02 (n= 30 GFP+ neurons), Q331K:shPP1α= 1.1 ± 0.06
(n= 31 GFP+ neurons), Q331K:shPP1β= 0.74 ± 0.03 (n= 30 GFP+ neurons), Q331K:shPP1γ= 0.89 ± 0.6 (n= 19 GFP+ neurons), Q331K:I-2= 0.98 ±
0.05 (n= 35 GFP+ neurons). Values are mean ± S.E.M. F(2,86)= 26.64, ****P < 0.0001 for CON groups; F(4,105)= 1.710, n.s.: not significant for GFP
groups; F(4,138)= 20.02, ###P= 0.0001, ####P < 0.0001 for G93A groups; F(4,138)= 20.02, ##P= 0.0089, ####P < 0.0001 for Q331K groups by one-way
ANOVA with Tukey’s post hoc analysis for multiple comparisons. c Quantification of cleaved caspase-3-positive neurons in GFP+ neurons with 40 nM
I-2 treatment or shRNA lenti-viral infection following transfection of mALS genes, over 72 h. GFP:CON= 7.67 ± 2.06 (n= 6 independent primary
culture), GFP:shPP1α= 35.61 ± 12.54 (n= 2 independent primary culture), GFP:shPP1β=8.28 ± 0.75 (n= 3 independent primary culture), GFP:shPP1γ
= 17.11 ± 4.65 (n= 3 independent primary culture), GFP:I-2= 7.5 ± 2.51 (n= 5 independent primary culture), G93A:CON= 26.59 ± 2.31 (n= 5
independent primary culture), G93A:shPP1α= 37.09 ± 5.51 (n= 2 independent primary culture), G93A:shPP1β= 18.39 ± 2.45 (n= 2 independent
primary culture), G93A:shPP1γ= 12.09 ± 2.63 (n= 3 independent primary culture), G93A:I-2= 13.79 ± 0.84 (n= 4 independent primary culture),
Q331K:CON= 34.83 ± 1.370 (n= 3 independent primary culture), Q331K:shPP1α= 32.39 ± 2.39 (n= 2 independent primary culture), Q331K:shPP1β
= 17.03 ± 6.39 (n= 3 independent primary culture), Q331K:shPP1γ=17.07 ± 1.44 (n= 3 independent primary culture), Q331K:I-2= 12.57 ± 2.60 (n= 3
independent primary culture). Values are mean ± S.E.M. F(2,11)= 41.29, ****P < 0.0001 for CON groups; F(4,14)= 7.230, ***P= 0.0007 for GFP groups;
F(4,11)= 14.03, ##P= 0.0096 for G93A:CON versus G93A: shPP1γ, ##P= 0.0073 for G93A:CON versus G93A: I-2; F(4,9)= 7.887, #P= 0.0327 for Q331K:
CON versus Q331K: shPP1β, #P= 0.0327 for Q331K:CON versus Q331K: shPP1γ, ##P= 0.0089 by one-way ANOVA followed by Tukey’s multiple
comparisons test. d Quantification of pyknotic cell in GFP+ neurons with 40 nM I-2 treatment or shRNA lenti-viral infection following transfection of
mALS genes, over 72 h. GFP:CON= 9.39 ± 2.33 (n= 6 independent primary culture), GFP:shPP1α= 45.01 ± 14.25 (n= 2 independent primary culture),
GFP:shPP1β= 11.08 ± 2.31 (n= 3 independent primary culture), GFP:shPP1γ= 15.40 ± 5.19 (n= 3 independent primary culture), GFP:I-2= 6.64 ± 2.67
(n= 5 independent primary culture), G93A:CON= 34.85 ± 4.25 (n= 6 independent primary culture), G93A:shPP1α=41.18 ± 6.97 (n= 2 independent
primary culture), G93A:shPP1β= 15.78 ± 0.16 (n= 2 independent primary culture), G93A:shPP1γ= 13.13 ± 4.84 (n= 3 independent primary culture),
G93A:I-2= 17.98 ± 3.12 (n= 5 independent primary culture), Q331K:CON= 42.76 ± 7.15 (n= 3 independent primary culture), Q331K:shPP1α=
38.71 ± 6.21 (n= 2 independent primary culture), Q331K:shPP1β= 21.69 ± 2.95 (n= 3 independent primary culture), Q331K:shPP1γ= 22.14 ± 1.44
(n= 3 independent primary culture), Q331K:I-2= 14.45 ± 2.93 (n= 3 independent primary culture). Values are mean ± S.E.M. F(2,12)= 17.58, **P=
0.0012, ***P= 0.0007 for each CON group; F(4,14)= .101, ***P= 0.0007 for each GFP group; F(4,13)= 6.49, #P= 0.0245 for G93A:CON versus G93A:
shPP1γ, #P= 0.0441 for G93A:CON versus G93A:I-2; F(4,9)= 7.405, #P= 0.0433 for Q331K:CON versus Q331K: shPP1β, #P= 0.0483 for Q331K:CON
versus Q331K: shPP1γ, ##P= 0.0080 by one-way ANOVA followed by Tukey’s multiple comparisons test. e Analysis of total neurite length in (a). GFP:
CON= 100 ± 8.70 (n= 57 GFP+ neurons), GFP:I-2= 115.90 ± 9.90 (n= 22 GFP+ neuron), GFP: shPP1α=130.3 ± 18.51 (n= 9 GFP+ neuron), GFP:
shPP1β=72.12 ± 8.25 (n= 16 GFP+ neuron), GFP:shPP1γ=60.66 ± 5.05 (n= 29 GFP+ neuron), G93A:CON= 61.61 ± 3.10 (n= 91 GFP+ neuron),
G93A:I-2= 106.3 ± 7.51 (n= 27 GFP+ neuron), G93A:shPP1α= 93.39 ± 13.05 (n= 21 GFP+ neuron), G93A:shPP1β= 57.56 ± 4.52 (n= 23 GFP+
neuron), G93A:shPP1γ= 88.06 ± 11.45 (n= 26 GFP+ neuron), Q331K:CON= 42.39 ± 3.47 (n= 25 GFP+ neuron), Q331K:I-2= 122.2 ± 10.61 (n= 21
GFP+ neuron), Q331K:shPP1α=128.8 ± 17.3 (n= 23 GFP+ neuron), Q331K:shPP1β= 60.97 ± 6.15 (n= 27 GFP+ neuron), Q331K:shPP1γ= 94.81 ±
11.55 (n= 37 GFP+ neuron),. Values are mean ± S.E.M. F(2,170)= 19.98, ****P < 0.0001 for each CON group;F(4,128)= 7.415, #P= 0.0106, ##P= 0.0025
for GFP:I-2 versus GFP:shPP1γ, ##P= 0.0057 for GFP:shPP1α versus GFP:shPP1γ; F(4,183)=9.91, #P= 0.0235, #P= 0.0089, ###P= 0.0008 for each G93A
group; F(4,128)= 10.63, ##P= 0.0044, ####P < 0.0001 for each Q331K group by one-way ANOVA followed by Tukey’s multiple comparisons test.
f Analysis of total axonal length in (a). GFP:CON= 100 ± 10.33 (n= 56 GFP+ neuron), GFP:I-2= 119.4 ± 11.51 (n= 22 GFP+ neuron), GFP: shPP1α=
141.4 ± 24.44 (n= 9 GFP+ neuron), GFP:shPP1β= 73.71 ± 9.06 (n= 16 GFP+ neuron), GFP:shPP1γ= 59.58 ± 6.13 (n= 29 GFP+ neuron), G93A:CON
= 54.08 ± 3.02 (n= 86 GFP+ neuron), G93A:I-2= 80.63 ± 4.57 (n= 27 GFP+ neuron), G93A:shPP1α= 02.8 ± 15.10 (n= 21 GFP+ neuron), G93A:
shPP1β= 58.73 ± 6.10 (n= 23 GFP+ neuron), G93A:shPP1γ= 95.06 ± 13.3 (n= 26 GFP+ neuron), Q331K:CON= 49.70 ± 7.46 (n= 28 GFP+ neuron),
Q331K:I-2= 131.7 ± 15.21 (n= 21 GFP+ neuron), Q331K:shPP1α= 145.8 ± 20.67 (n= 23 GFP+ neuron), Q331K:shPP1β= 60.02 ± 7.01 (n= 27 GFP+
neuron), Q331K:shPP1γ= 98.4 ± 12.79 (n= 37 GFP+ neuron). Values are mean ± S.E.M. F(2, 167)= 15.91, ***P= 0.0001, ****P < 0.0001 for each CON
group; F(4,127)= 5.083, #P= 0.0386 for each GFP group;F(4,178)= 9.565, #P= 0.0356, ###P= 0.0002, ####P < 0.0001 for each G93A group;F(4,131)=
4.236, #P= 0.0395, ###P= 0.0005, ####P < 0.0001 for each Q331K group by one-way ANOVA followed by Tukey’s multiple comparisons test.
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exhibit common symptoms such as MN death, axonal
degeneration, and mitochondrial defects44,45. In this
study, we identified that dephosphorylation of Drp1 is
mediated by pathological activation of PP1 induced by
SOD1 G93A or TDP-43 Q331K overexpression in cellular
models, and in mouse models with the G93A mutation.
Blocking the PP1-Drp1 cascades effectively prevented
mitochondrial defects and subsequent neurodegeneration
in various ALS models. The gain-of-function mutation of
SOD1 is proposed to impair protein misfolding-mediated
clearance pathways, including ubiquitin-dependent pro-
teolysis, protein aggregations, and autophagy, in addition
to causing mitochondrial dysfunction46–48. On the other
hand, TDP-43 is an RNA-binding protein that may trigger
defects in mRNA processing, with multiple consequences
including defective nucleocytoplasmic transport49, mito-
chondrial deficits, and abnormalities in mitophagy50,51.
Given that these different causative mutations commonly
compromise mitochondrial function, which can be pre-
vented by the blockade of PP1-Drp1 cascades, these form
an important common biological hub for ALS pathology,
and may be important therapeutic targets against the
multiple pathological features of ALS. Further analysis
with different ALS models caused by other types of
Fig. 5 Effects of the blockade of PP1 on the complex I activity of mitochondria in the ALS model. a The histological image of NADH
dehydrogenase activity and biochemical measurement of complex I activity on the MNs of the lumbar spinal cord in G93A and WT mice at 60 days of
age. The inset graph shows the average of the complex I activity value. WT= 99.74 ± 3.83 (n= 4 mice), G93A= 62.9 ± 12.37 (n= 4 mice). Values are
mean ± S.E.M. F(1,6)= 2.87, *P= 0.0284 by two-sided Student’s t-test. Scale bar, 100 μm. b The activity of mitochondrial complex I in primary cortical
neurons cultured from WT and G93A mice following treatment with 25 µM Mdivi-1 or 80 nM I-2 for 72 h. WT:CON= 99.69 ± 6.81 (n= 3 independent
primary culture), WT:Mdivi-1= 99.37 ± 8.55 (n= 3 independent primary culture), WT:I-2= 113.9 ± 9.12 (n= 4 independent primary culture), G93A:
CON= 77.36 ± 5.33 (n= 5 independent primary culture), G93A:Mdivi-1= 88.09 ± 7.70 (n= 8 independent primary culture), G93A:I-2= 113.7 ± 7.09
(n= 7 independent primary culture). Values are mean ± S.E.M. F(1,6)=2.58, *P= 0.0421 for WT:CON versus G93A:CON by by two-sided Student’s t-test;
F(2,17)=6.22, #P= 0.0110 for G93A:CON versus G93A:I-2, n.s.= not significant group by one-way ANOVA followed by Tukey’s multiple comparisons
test. c The representative images and measurement of MMP in GFP+ primary cortical neurons following mALS gene transfection with 25 µM Mdivi-1
or 80 nM I-2 treatment for 72 h. GFP:CON= 1 ± 0.07 (n= 15 GFP+ primary cortical neurons), GFP:Mdivi-1= 0.73 ± 0.08 (n= 16 GFP+ primary cortical
neurons), GFP:I-2= 0.92 ± 0.06 (n= 16 GFP+ primary cortical neurons), G93A:CON= 0.66 ± 0.06 (n= 23 GFP+ primary cortical neurons), G93A:Mdivi-
1= 0.64 ± 0.07 (n= 17 GFP+ primary cortical neurons), G93A:I-2= 0.96 ± 0.07 (n= 22 GFP+ primary cortical neurons), Q331K:CON= 0.64 ± 0.07 (n=
17 GFP+ primary cortical neurons), Q331K:Mdivi-1= 0.57 ± 0.04 (n= 11 GFP+ primary cortical neurons), Q331K:I-2= 0.97 ± 0.10 (n= 16 GFP+
primary cortical neurons). Values are mean ± S.E.M. F(2,52)= 7.529, **P= 0.0030 for GFP:CON versus G93A:CON, **P= 0.0037 for GFP:CON versus
Q331K:GFP; F(2,44)= 3.86, *P= 0.0268 for GFP:CON versus GFP:Mdivi-1; F(2,59)= 7.184, **P= 0.0048 for G93A:CON versus G93A:I-2; F(2,41)= 6.87,
*P= 0.0119 for Q331K:CON versus Q331K:I-2 by one-way ANOVA followed by Tukey’s multiple comparisons test. Scale bar, 20 μm.
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mutation is necessary to expand upon this intriguing
notion (Fig. 7).
Mitochondrial defects have been considered important
mediators in the progression of multiple neurodegenera-
tive diseases, including ALS. In ALS models, the
mitochondria are hyper-fragmented, and their axonal
transport, ATP synthesis, and mitophagic removal are
greatly affected28,52,53. Drp1 has been proposed as a key
player in this mitochondria-related ALS pathology
because several causative gene mutations associated with
Fig. 6 (See legend on next page.)
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ALS promote Drp1 activity36,54–57. The induction of Drp1
activity is apt to promote cell death signaling via multiple
mediating processes39,58. Thus, the inhibition of Drp1 led
to the exhibition of therapeutic effects in the G93A mouse
model59. Our current observations further confirmed this
notion in SOD1 mutations and extended it to include ALS
models with the TDP-43 mutation. Notably, we observed
the dephosphorylation of Drp1 S616 sites in several ALS
models, and Drp1 S616 has been widely considered as an
activating phosphorylation site30. However, we previously
found that phosphorylation of Drp1 S616 by cyclin-
dependent kinase 5 (CDK5) inhibited the translocation of
Drp1 to the mitochondria in neurons, resulting in reduced
mitochondrial fission36,60. Given that CDK5 is specifically
expressed in post-mitotic neurons, this cascade appeared
to be specific to neurons at that particular stage. In this
respect, the dephosphorylation of Drp1 S616 in the neu-
rons of ALS models appears to promote Drp1 activation.
We found that a blockade of dephosphorylation prevented
Drp1-related ALS symptoms, which supports our current
hypothesis.
While Drp1 inhibition proved to be clearly beneficial,
there were nonetheless several reasons for us to seek
upstream targets, such as PP1, for ALS therapy. Pre-
viously, we observed that a blockade of Drp1 activity in
normally developing chick MNs resulted in an increase in
programmed cell death and the impairment of axonal
growth61. Considering that mitochondrial fusion and fis-
sion are essential events for cellular homeostasis28,30,53,
there is a narrow range in which mitochondrial dynamics
must be maintained for optimal survival. In concurrence
with our previous observations in developing MNs, we
also found that the suppression of Drp1 activation had
little benefit for axonal growth. It should also be noted
that Drp1 performs many functions in addition to mito-
chondrial fission. Drp1 can interact with many different
proteins localized at different subcellular locations,
thereby being involved in many biological processes such
as peroxisomal fragmentation, vesicle endocytosis/recy-
cling, MMP changes, and cytoskeletal remodeling29,62.
Indeed, restoration of Drp1 activity to a normal physio-
logical level in the long-term may be difficult to achieve,
meaning that alternative robust and druggable targets for
ALS therapy are highly desirable.
Here we identified PP1 as an upstream phosphatase
responsible for the dephosphorylation of Drp1 and tested
whether regulation of PP1 activity is beneficial for the
suppression of ALS-related pathological consequences.
PP1 is a serine/threonine phosphatase and exists as a
cellular holoenzyme composed of catalytic and regulatory
subunits38,63,64. It is required for many cellular functions,
including cell division, apoptosis, cytoskeletal organiza-
tion, protein synthesis, and metabolism38. Moreover, it
has been reported that PP1 activity is associated with
several neurodegenerative diseases. For instance, the
dephosphorylation of mutant leucine-rich repeat kinase 2
(LRRK2) by PP1 is increased in Parkinson’s disease65.
Previous studies reported that, in Alzheimer’s disease, tau
(see figure on previous page)
Fig. 6 Effects of the suppression of PP1 in ALS-associated zebrafish and human iPS cell models. a Motor axons of zebrafish treated with
200 nM I-2 or 100 nM OA daily for 2 days following transient expression of G93A or Q331K mutations. The red dashed-line square indicates a
magnified image of motor axons. The blue arrowhead indicates the ventral projection of the motor axon, and the yellow arrowhead indicates
neuromuscular junction. b Analysis of axonal defects in (a). CON= 0.14 ± 0.36 (n= 14 zebrafish), G93A:Non= 2.93 ± 0.29 (n= 14 zebrafish), G93A:I-2
= 0.86 ± 0.23 (n= 14 zebrafish), G93A:OA= 0.73 ± 0.21 (n= 30 zebrafish), Q331K:Non= 3.71 ± 0.19 (n= 14 zebrafish), Q331K:I-2= 1.00 ± 0.27 (n= 14
zebrafish), Q331K:OA= 1.43 ± 0.39 (n= 14 zebrafish). Values are mean ± S.E.M. F(2,39)= 81.83, ****P < 0.0001 for CON versus G93A:Non and CON
versus Q331K:Non;F(2,55)= 21.78, ####P < 0.0001 for G93A:CON versus G93A:I-2 and G93A:CON versus G93A:OA; F(2,39)= 25.12, &&&&P < 0.0001 for
Q331K:CON versus Q331K:I-2 and Q331K:CON versus Q331K:OA by one-way ANOVA followed by Tukey’s multiple comparisons test. c Analysis of
axonal length in (a). CON= 162.5 ± 2.77 (n= 6 zebrafish), G93A:Non= 122 ± 2.96 (n= 13 zebrafish), G93A:Mdivi-1= 141.4 ± 2.45 (n= 13 zebrafish),
G93A:I-2= 151.1 ± 1.56 (n= 14 zebrafish), Q331K:Non= 23.3 ± 5.82 (n= 10 zebrafish), Q331K:Mdivi-1= 141.3 ± 3.37 (n= 14 zebrafish), Q331K:I-2=
145.3 ± 3.14 (n= 14 zebrafish). Values are mean ± S.E.M. F(2,26)= 21.27, ****P < 0.0001 for CON versus G93A:Non and CON versus Q331K:Non;F(2,37)
= 39.83, ####P < 0.0001 for G93A:CON versus G93A:Mdivi-1 and G93A:CON versus G93A:I-2, #P= 0.0156 for G93A:Mdivi-1 versus G93A:I-2;F(2,35 )=
7.755, &P= 0.0104 for Q331K:CON versus Q331K:Mdivi-1, &&P= 0.0017 for Q331K:CON versus Q331K:I-2 by one-way ANOVA followed by Tukey’s
multiple comparisons test. d Immunostaining of cleaved caspase-3 and ChAT in 3-week-old MNs of control and mTDP-43 lines treated with 80 nM I-2
every other day for 2 weeks. Scale bar, 25 μm. e Measurement of mitochondrial length in 3-week-old MNs of control and mTDP-43 lines treated with
80 nM I-2 every other day for 2 weeks. CON:I-2(−)= 2.42 ± 0.07 (n= 38 ChAT+ neurons), CON:I-2(+)= 3.24 ± 0.13 (n= 37 ChAT+ neurons), mTDP-
43:I-2(−)= 1.75 ± 0.06 (n= 38 ChAT+ neurons), mTDP-43:I-2(+)= 2.63 ± 0.11 (n= 36 ChAT+ neurons). Values are mean ± S.E.M. F(1,74)= 6.837,
****P < 0.0001 for CON:I-2(−) versus mTDP-43:I-2(−); F(1,73)= 5.538, ****P < 0.0001 for CON:I-2(−) versus CON:I-2(+); F(1,72)= 6.840, ****P < 0.0001
for mTDP-43:I-2(−) versus mTDP-43:I-2(+) for by two-sided Student’s t-test. f Quantification of cleaved caspase-3+ cell in human iPS-derived ChAT+
neuron in (d). CON:I-2(−)= 7.86 ± 0.42 (n= 3 iPS cell lines), CON:I-2(+)= 7.96 ± 0.89 (n= 3 iPS cell lines), mTDP-43:I-2(−)= 31.47 ± 3.34 (n= 3 iPS cell
lines), mTDP-43:I-2(+)= 15.67 ± 2.06 (n= 3 iPS cell lines). Values are mean ± S.E.M. F(1,4)= 7.01, **P= 0.0022 for CON:I-2(−) versus mTDP-43:I-2(−);
F(1,4)= 4.03, *P= 0.0158 for mTDP-43:I-2(−) versus mTDP-43:I-2(+) for by two-sided Student’s t-test. g Quantification of pyknotic cell in ChAT+
neuron in (d). Values are mean ± S.E.M. (N= 3 lines in CON and mTDP-43; *p < 0.05, **p < 0.01 in two-sided Student’s t-test). CON:I-2(−)= 14.37 ± 0.84
(n= 3 iPS cell lines), CON:I-2(+)= 10.43 ± 0.75 (n= 3 iPS cell lines), mTDP-43:I-2(−)= 7.11 ± 4.04 (n= 3 iPS cell lines), mTDP-43:I-2(+)= 18.99 ± 1.71
(n= 3 iPS cell lines). Values are mean ± S.E.M. F(1,4)= 5.514, **P= 0.0053 for CON:I-2(−) versus mTDP-43:I-2(−); F(1,4)= 4.131, *P= 0.0145 for mTDP-
43:I-2(−) versus mTDP-43:I-2(+) for by two-sided Student’s t-test.
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phosphorylation was induced by GSK3β, which is acti-
vated by PP166,67, and I-2 prevented amyloid-β oligomer
(AβO)-induced defects in brain-derived neurotrophic
factor (BDNF)-containing vesicle transport67. In this
study, we found that PP1 activity was increased in the
SOD1 G93A ALS mouse model before the onset of the
disease, and the blockade of PP1 activity prevented
mitochondrial defects. Importantly, the PP1 blockade
prevented axonal degeneration and restored the complex
I activity of the mitochondria in the ALS model, results
that were not achieved by the inhibition of Drp1 in our
model. We found that the different PP1 isoforms may
mediate different consequences of ALS-related patholo-
gies because selective inhibition of each isoform resulted
in different outcomes with respect to mitochondrial
fragmentation, axonal growth, and cell survival. Das et al.
reported that Sephin1, a novel inhibitor of PP1 and
PPP1R15α (GADD34) binding, prevented the aggregation
of mutant SOD1 G93A protein and MN death in an ALS
model, improving motor deficiency in SOD1 G93A
mice68. They proposed that Sephin1 inhibited the phos-
phorylation of eukaryotic initiation factor 2 (eIF2α)
without affecting PP1 catalytic activity. On the other
hand, we observed that the inhibition of PP1 activity
improved ALS-related pathologies and failed to observe
any dephosphorylation of eIF2 α induced by I-2 treatment
(Supplementary Fig. 4). Therefore, PP1 may affect the
propagation of ALS-related pathologies in catalytic
activity-dependent or -independent manners.
While PP1 appears to affect ALS pathology via Drp1
dephosphorylation, it must also have other substrates. For
instance, mitochondrial complex I, which is composed of
44 subunits69, is a pacemaker of the mitochondrial
respiratory system70,71. Thus, impairment of complex I is
often reported in ALS models1,2. Complex I deficiency
represents severe defects within the mitochondrial system
and induces ALS via impairment of mitochondrial
metabolism72–74. Some subunits in complex I, which are
closely linked to its activity, are regulated by (de)phos-
phorylation63,75–77. Therefore, although we cannot com-
pletely rule out the possibility that the pathological effect
of PP1 activation is also mediated by Drp1, we favor the
idea that pathological induction of PP1 activity may
impair other cellular processes, including mitochondrial
complex activity, independently of Drp1, via depho-
sphorylation of its target protein(s). Unbiased identifica-
tion of PP1 targets and the further assessment of the
precise molecular targets of PP1 should be addressed in
the future to clarify this and related issues.
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Fig. 7 Hypothetical schematic diagram: abnormal promotion of
PP1 activity in the MNs of ALS and dephosphorylation of the
S616 site of Drp1, resulting in the induction of mitochondrial
fragmentation. Also, abnormal PP1 activity decreases the
mitochondrial complex I activity, leading to axonal degeneration.
Thus, the blockade of PP1 activity reduces the ALS-induced
mitochondrial fission and improves mitochondrial functions such as
the complex I activity of the mitochondrial electron transport chain
and membrane potential, resulting in improvement of axonal
impairment. Therefore, inhibition of excessive PP1 activity may
promote MN survival by improving mitochondrial function.
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